Everolimus is an orally active mTOR inhibitor, and VEGF is a potent proangiogenic protein that plays an important role in tumor angiogenesis [10] and acts by binding to the VEGFR on endothelial cells [46]. The gene discussed is MTOR; the disease is neoplasm.